11-Hydroxy-THC Explained: Why Edibles Hit Different, and Why Your 10mg Is Not Your Friend's 10mg

"Edibles hit different" is the most repeated sentence in cannabis, and it is half right. The right half has a molecule behind it. Swallowed THC goes through the liver before it goes anywhere else, and the liver turns a large share of it into 11-hydroxy-THC, a metabolite the first human studies found at least as potent as THC and quicker to the brain. Smoke the same THC and the liver sees it later and in smaller portions, so very little of that metabolite ever forms. That is a real difference in chemistry, and it is why nobody on this site tells you a 10mg gummy equals a 10mg puff.

The wrong half is the weight the folklore hangs on that molecule. The heavy, endless, never-again edible night is mostly a dosing and delay problem: an onset window of 30 minutes to 2 hours that invites a second piece, a peak at 2 to 3 hours, and a dose chosen with no feedback at all. 11-hydroxy-THC takes the blame for a decision made at the 45-minute mark. The same first-pass story explains what no brand prints on the tin. By the FDA's own label for prescription THC, only 10 to 20 percent of a swallowed dose reaches the bloodstream, and where you land in that range is set by your gut, your liver enzymes and one gene. Your 10mg gummy and your friend's 10mg gummy are not the same dose. They were never going to be.

What is 11-hydroxy-THC?

11-hydroxy-THC is the first thing your liver makes from THC. The enzyme CYP2C9 adds a hydroxyl group at the molecule's eleventh carbon, the product reaches the brain and produces the effects THC produces, and the liver then oxidizes it onward into THC-COOH, the inactive leftover that urine tests look for.

In 1972, Lemberger, Crabtree and Rowe infused 11-hydroxy-THC into volunteers and reported in Science that it produced effects lasting several hours and that THC is converted into it in man, with the metabolite "responsible for the effects." Perez-Reyes and colleagues, in Science the same summer, infused both compounds and called them equally potent. A year later Lemberger's group gave nine casual smokers 1mg of each by vein: the 11-hydroxy version produced a marked tachycardia and a high within 3 to 5 minutes, while THC's peak high arrived 10 to 20 minutes in. Equal strength, faster arrival, and Huestis's 2007 review calls it the equipotent metabolite. The multiples that circulate on dispensary blogs (three times, five times, seven times) trace to no person.

The enzyme assignment is settled too. Watanabe and colleagues ran THC through human liver microsomes and found CYP2C9 doing the 11-hydroxylation while CYP3A4 handled a minor hydroxylation elsewhere on the molecule, and the Marinol label says the same in plainer words: CYP2C9 and CYP3A4 are the primary enzymes, with CYP2C9 forming the primary active metabolite. That enzyme name comes back in the section about your friend.

The chain runs on past the active metabolite. The liver oxidizes 11-hydroxy-THC into THC-COOH, which does nothing to the brain and everything to a drug test, and the oral route makes more of it: Newmeyer's NIDA group dosed the same people by smoking, vaporizer and brownie and found significantly greater THC-COOH after the brownie. Our drug-testing piece follows that leftover into the cup.

Why do edibles hit harder than smoking the same amount?

Because after a swallowed dose two active molecules circulate at similar levels instead of one. Wall and colleagues measured the plasma ratio of 11-hydroxy-THC to THC at 1:10 to 1:20 after intravenous THC and 0.5:1 to 1:1 after oral THC, and the Marinol label describes the two at approximately equal concentrations.

Wall's 1983 study dosed men and women by vein and by mouth and tracked both molecules. After intravenous THC the metabolite ran at a tenth to a twentieth of the parent; after oral THC, at half to equal. The liver also sent far more of the swallowed dose out through the bile: fecal excretion over 72 hours ran 48 to 53 percent after oral dosing against 25 to 30 after intravenous. The edible route produces a second active molecule at parity with the first, and throws away more of both.

Here is the part the folklore skips. The absolute numbers are tiny. In the Johns Hopkins brownie study, mean whole-blood THC peaked at 1 ng/mL after a 10mg brownie, 3.5 after 25mg and 3.3 after 50mg, with 11-hydroxy-THC peaking at similar levels and times, and Vandrey's team wrote that the concentrations were low compared with inhalation. The effects were dose-dependent anyway, peaking at 1.5 to 3 hours and lasting 6 to 8. Two molecules at low concentration for a long time is a different shape of experience from one molecule at high concentration for a short one, and "heavier" is a fair word for it. "Stronger" is a word for the dose.

And the dose is where the night goes wrong. The figures on our duration guide, drawn from Grotenhermen's review, are an onset of 30 minutes to 2 hours (typical delay 30 to 90 minutes), a peak at 2 to 3 hours, and 4 to 8 hours of main effects, up to 12 at higher doses. A smoker gets feedback in minutes and stops. An eater gets nothing for an hour, decides the gummy was weak, eats another, and meets both at the peak. Schlienz's dose-response study, the source of the tiers on our dosing guide, found 10mg produced clear effects without measurable impairment while 25 and 50mg impaired people. The gap between a pleasant evening and the never-again story is one extra piece.

How much of a 10mg gummy actually reaches your blood?

Between 1mg and 2mg of THC, by the FDA label for Marinol, which states that oral dronabinol is 90 to 95 percent absorbed and that 10 to 20 percent of the dose reaches the systemic circulation after first-pass metabolism. Huestis's pharmacokinetics review puts the oral range at 4 to 20 percent, and the cookie study she cites measured 6.

The label makes the arithmetic blunt. Section 12.3 says dronabinol, which is THC, is almost completely absorbed after a single oral dose and that "only 10 to 20% of the administered dose reaches the systemic circulation." Huestis lists why the range runs so wide: variable absorption, degradation in the stomach, and significant first-pass metabolism to active 11-hydroxy-THC and inactive products in the liver. Her cleanest example, Ohlsson's 1980 chocolate cookie carrying 20mg of THC, produced peak blood THC of 4.4 to 11 ng/mL between one and five hours later and an estimated bioavailability of 6 percent. She describes oral THC as yielding "low and irregular" plasma concentrations. Irregular is the word to keep.

Irregular looks like this in a lab. In the NIDA brownie session Newmeyer reported in 2017, frequent smokers' peak blood THC averaged 17.7 micrograms per liter, with a range of 8.0 to 36.1, and occasional smokers averaged 8.2, with a range of 3.2 to 14.3. One recipe, a four-fold spread inside each group and a two-fold gap between them. The milligram number on a gummy is a statement about the gummy. It was never a statement about you.

Irregular looks like this outside a lab. In December 2020 a Growers Network forum member posting as kkustom described 37 years of near-daily smoking and a complete inability to feel edibles: a neighbor's butter edibles that flatten experienced adults, dispensary tinctures, six or seven homemade candies eaten during the cooking, nothing. The post mentions, almost in passing, no gallbladder, no ascending colon and about six feet of small intestine lost to Crohn's disease. The replies went straight to decarboxylation temperatures and lecithin; the poster's own next-day thought was liver enzymes. Before the liver gets a vote, the gut has to deliver a fat-soluble molecule across a wall that in this case is largely missing, and a label cannot know that either.

Why does the same edible hit my friend harder than me?

Because the enzyme that makes 11-hydroxy-THC comes in versions. Sachse-Seeboth and colleagues gave oral THC to 43 volunteers and found median THC exposure three times higher in people carrying two copies of the CYP2C9*3 variant than in normal metabolizers, with 70 percent less of the inactive metabolite and a trend toward more sedation.

The study is small and the best there is. Sachse-Seeboth's group in Göttingen genotyped 43 volunteers, gave each oral THC and sorted the blood curves by CYP2C9 variant. The common *2 variant changed nothing measurable. Two copies of *3 tripled the median area under the THC curve and cut the inactive THC-COOH by 70 percent, the pattern of an enzyme working at a third of normal speed. Bland and colleagues had measured that slowdown in a dish four years earlier, with the intrinsic clearance of CYP2C9.2 and CYP2C9.3 at about 30 percent of the wild type. The double *3 carriers also trended toward more sedation, the polite research term for the friend asleep on the floor at 9pm after half of what you took.

Two copies of *3 is rare, and our dose chart guide works out how rare, along with the other variable most dose charts ignore: the pooled Johns Hopkins data it covers found women reached higher peak 11-hydroxy-THC after oral cannabis than men and rated the effect stronger, adjusted for weight. The point here is narrower. The enzyme that makes the metabolite everyone blames is the enzyme whose speed varies three-fold between two people holding the same tin, and nothing on the tin can tell you which one you are.

The table puts the three routes beside each other on the four numbers this page is about.

Do fast-acting edibles skip the liver?

Partly, which is the whole product. Encapsulated or nano-emulsified THC absorbs through the mouth and upper gut, so less of the dose takes the liver route and less 11-hydroxy-THC gets made. Wana claims 5 to 15 minutes to onset and 2 to 4 hours for its Quick line, against 45 to 90 and 4 to 6 for Classic.

Huestis notes that Sativex, the prescription THC and CBD spray, is dosed under the tongue precisely to avoid first-pass metabolism, and that rectal THC achieves roughly twice the oral bioavailability "due to higher absorption and lower first-pass metabolism." Get THC across the mouth lining or the upper gut and the liver meets it later and in smaller portions, the way it meets smoke. The cost of skipping the liver is the metabolite the liver would have made, which is why the brand promising the fast onset also promises the shorter high; our fast-acting explainer carries Wana's figures. No peer-reviewed trial has timed any retail fast-acting gummy.

The market has priced the liver. On the Star Buds menu in Garden City, Colorado on November 7, 2026, Wana's Classic assorted 10-pack at 100mg was $17 and the Quick 1:1 Strawberry Margarita pack (Wana now calls it Bright Berry Lime), 100mg of THC with 100mg of CBD riding along, was $20. (Star Buds labels that pack a 10-count; Silver Stem and Callie's, also in Colorado, say 20 gummies at 5mg of each, and every listing agrees on the package total.) Three dollars, three cents per milligram of THC, for the encapsulation and the CBD. A fee for skipping an organ, and as organ-related fees go, a modest one.

Whether that is money well spent is a question about why you bought the edible. The patient dosing for sleep or overnight pain was buying the long tail, and the fast version removes it. The patient who needs to know within 20 minutes whether a breakthrough dose was enough was buying feedback. Our fast-acting ranking sorts the shelf on those terms.

What changes how much 11-hydroxy-THC you make?

Any drug that inhibits or induces CYP2C9 or CYP3A4, which the Marinol label flags in its interaction section, and the measured effects are large. In Stott's 2013 study for GW Pharma, 400mg of ketoconazole, a CYP3A4 inhibitor, raised peak 11-hydroxy-THC 204 percent after a THC and CBD spray, and rifampicin, an inducer, cut it 87 percent.

Stott's trial is the clearest human demonstration that the liver's share of THC is adjustable. Thirty-six healthy men took four sprays of Sativex (10.8mg of THC with 10mg of CBD) alone and again after one of three drugs. Rifampicin cut peak THC by 36 percent and peak 11-hydroxy-THC by 87 percent; ketoconazole raised them 27 and 204 percent; omeprazole, a CYP2C19 inhibitor, changed nothing. The metabolite moved far more than the parent in both directions: a drug that touches these enzymes changes the size of the edible effect more than it changes the size of the dose. The Marinol label's list of protein-bound drugs to watch alongside dronabinol starts with warfarin.

CBD is asked about more than any prescription drug, and the answer is smaller than the warnings suggest. Huestis reports that adding CBD to oral THC only partially inhibited the CYP2C hydroxylation to 11-hydroxy-THC, an effect small against the variability between people. Our antidepressants guide reads the Epidiolex label on the same question: CBD is a moderate CYP2C19 inhibitor, and 750mg twice a day left a CYP3A4 test drug unchanged.

What the people who report consistent results with edibles have in common is a habit the label never suggests. They describe holding one product at one dose for several nights before changing anything, because what they are calibrating is a liver, and a liver only reports in afterward. The gummy's job is to be the same every time. On the evidence above, you are the variable.